Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-002303Source: DataRank Database

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma is a research paper published in Journal for ImmunoTherapy of Cancer (2021). On theSindex it has a DataRank of 0.621. It has been cited 62 times.

N/A

0.621DataRank · unranked

Scored on demand from live citation data

Open Access62 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 3.41)OA: goldTopics (46)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.621

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (25)

Zachary Braunstein ORCID,Aashish Katapadi ORCID,Kyle Porter ORCID,Michael Biersmith ORCID,Avirup Guha ORCID

Live enrichment

PubMed:34429331 PMC:PMC8386216 OpenAlex:https://openalex.org/W3195755447

National Cancer Institute

Grant: P30 CA016058

Foundation for the National Institutes of Health

Grant: K12CA133250

Foundation for the National Institutes of Health

Grant: KL2-TR002734

Foundation for the National Institutes of Health

Grant: R01HL127442-01A1

NCATS NIH HHS

Grant: KL2 TR002734

NHLBI NIH HHS

Grant: K23 HL155890

NCI NIH HHS

Grant: T32 CA090223

NHLBI NIH HHS

Grant: R01 HL127442

National Institutes of Health

Grant: 3P30CA016058-15S1

CORE--HORMONE RECEPTOR LABORATORY

National Institutes of Health

Grant: 1KL2TR002734-01

Institutional Career Development Core

National Institutes of Health

Grant: 5K23HL155890-02

Early Detection and Mechanisms of Cancer Immunotherapy Associated Cardiotoxicity

National Institutes of Health

Grant: 5R01HL127442-04

Ectonucleotidases in ischemic heart disease

National Institutes of Health

Grant: 2K12CA133250-16

OSU K12 Training Grant in Oncology

FWCI

3.41

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by-nc

journalhttps://jitc.bmj.com/content/jitc/9/8/e002303.full.pdf

publisherhttps://jitc.bmj.com/content/jitc/9/8/e002303.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1136/jitc-2020-002303

journalhttps://doi.org/10.1136/jitc-2020-002303

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34429331

Fields of Study

CAR-T cell therapy researchCancer Immunotherapy and BiomarkersLymphoma Diagnosis and Treatment03 medical and health sciences0302 clinical medicineFemaleHumansImmunotherapyLymphomaMaleMiddle AgedNeurotoxicity SyndromesReceptors, Antigen, T-Cell

MeSH Terms

FemaleHumansImmunotherapyLymphomaMaleMiddle AgedReceptors, Antigen, T-CellNeurotoxicity Syndromes

Keywords

Chimeric antigen receptorMedicineCAR T-cell therapyLymphomaToxicityAntigenOncologyT cellImmunologyCancer researchInternal medicineImmune systemReceptorsImmunotherapyHematologic neoplasmsChimeric AntigenMaleReceptors, Antigen, T-CellNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle AgedImmunotherapy BiomarkersHumansFemaleNeurotoxicity SyndromesRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma

10.6084/m9.figshare.26507203.v1figshare

Additional file 1 of Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma

10.6084/m9.figshare.26507203figshare